1. Home
  2. ALAR vs CUE Comparison

ALAR vs CUE Comparison

Compare ALAR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$8.54

Market Cap

57.1M

Sector

Technology

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.31

Market Cap

49.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
CUE
Founded
2013
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.1M
49.6M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
ALAR
CUE
Price
$8.54
$0.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$27.00
$3.00
AVG Volume (30 Days)
89.3K
1.3M
Earning Date
11-26-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$36,305,000.00
$7,100,000.00
Revenue This Year
$31.17
N/A
Revenue Next Year
$30.14
$25.00
P/E Ratio
$53.14
N/A
Revenue Growth
15.03
N/A
52 Week Low
$5.45
$0.23
52 Week High
$18.00
$1.75

Technical Indicators

Market Signals
Indicator
ALAR
CUE
Relative Strength Index (RSI) 44.30 33.41
Support Level $7.50 $0.23
Resistance Level $9.37 $0.33
Average True Range (ATR) 0.47 0.05
MACD 0.32 -0.00
Stochastic Oscillator 61.75 27.03

Price Performance

Historical Comparison
ALAR
CUE

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: